| Monday, May 17 |
|
1930 -2200
|
Welcome Reception
Light refreshments will be served |
Tuesday, May 18 |
|
| 0730 - 0830 |
Breakfast |
| 0830 - 0840 |
Welcome from Gordon Francis
|
| 0840 - 1045 |
Apolipoprotein and HDL Structure
Discussion Leader: Michael Phillips (The Children's Hospital of Philadelphia) |
0840 - 0905
|
ApoA-I and HDL Structural Model by Electron Cryo-tomography
Gary Ren (University of California, San Francisco) |
0905 - 0930
|
The Black and White of Mouse HDL
Godfrey Getz (The University of Chicago) |
0930 - 0955
|
The Structure of Apolipoprotein A-I in Real HDL Particles
Sean Davidson (University of Cincinnati) |
0955 - 1020
|
The Double Superhelix Model of High Density Lipoprotein
Stanley Hazen (Cleveland Clinic Foundation) |
1020 - 1045
|
ApoA-I on HDL: When Structure Meets Function
Michael Oda (Children's Hospital Oakland Research Institute)
|
| 1045 - 1105 |
Break
|
| 1105 - 1305 |
ABCA1 Action and Regulation
Discussion Leader: Michael Hayden (Centre for Molecular Medicine & Therapeutics) |
1105 - 1130
|
Membranes Under Influence: The Role of the ABCA1 Transporter
Giovanna Chimini (CIML - Parc Scientifique & Technologique de Luminy) |
1130 - 1155
|
ABCA1-mediated Cellular Lipid Efflux and HDL Biogenesis
Michael Philips (The Children's Hospital of Philadelphia) |
1155 - 1220
|
Lysosomal Cholesterol as a Regulator of, and Substrate for, ABCA1
Gordon Francis (UBC James Hogg Research Centre) |
1220 - 1240
|
ABCA1: The Direct Link between the Cardioprotective Effects of Cholesterol Export and Anti-Inflammation
Chongren Tang (University of Washington) |
1240 - 1305
|
A Novel Post-translational Regulation of ABCA1 to Keep ABCA1 on Standby for HDL Formation in Acute Cholesterol Accumulation
Kazumitsu Ueda (Kyoto University)
|
| 1305 |
Lunch
|
| 1400 - 1645 |
Poster Viewing |
| 1645 - 1710 |
ABCG1
Discussion Leaders: Wendy Jessup (University of New South Wales) and Arnold von Eckardstein (Universitätsspital Zürich Institut) |
1645 - 1710
|
Revisiting the Function of ABCG1
Peter Edwards (University of California, Los Angeles)
|
| 1710 - 1900 |
Plasma HDL-C: Novel Determinants and Correlation With Risk for Atherosclerotic Disease
Discussion Leaders: Wendy Jessup (University of New South Wales) and Arnold von Eckardstein (Universitätsspital Zürich Institut) |
1710 - 1725
|
Effects of Endothelial Lipase Loss-of-Function Mutations on HDL-C Levels in the General Population
Ian Tietjen (Xenon Pharmaceuticals Inc.) |
1725 - 1740
|
Deficiency of the WW Domain-Containing Oxidoreductase (WWOX) Impairs the HDL Biogenesis Pathway
Iulia Iatan (McGill University) |
1740 - 1820
|
Plasma HDL-C: New Genes, and Some Surprising Findings
Sek Kathiresan (Broad Institute) |
1820 - 1845
|
Mutations Affecting HDL Cholesterol Levels Predispose to Atherosclerosis
John Kastelein (Academisch Medisch Centrum Amsterdam) |
| 1845 - 1900 |
Discussion |
| 1900 |
Dinner On Own |
| |
|
| Wednesday, May 19 |
|
| 0730 - 0830 |
Breakfast
|
| 0830 - 1000 |
Protective Actions of HDL
Discussion Leader: Miranda van Eck (Leiden/Amsterdam Center for Drug Research) |
0830 - 0855
|
Novel Insights Into the Regulation of Reverse Cholesterol Transport
Albert Groen (Academic Medical Center Liver Center) |
0855 - 0920
|
Extracellular Cholesterol-Rich Microdomains Generated by Human Macrophages and their Potential Function in Reverse Cholesterol Transport
Howard Kruth (National Institutes of Health) |
0920 - 0935
|
HDL Protects Macrophages Against Free Cholesterol-Induced Apoptosis In An SR-BI-dependent Manner
Bernardo Trigatti (McMaster University) |
0935 - 1000
|
Protective Effects of HDL Beyond Cholesterol Transport
Philip Barter (The Heart Research Institute)
|
| 1000 - 1115 |
ABCA1 and HDL in Other Disease States
Discussion Leader: John Parks (Wake Forest University Health Sciences) |
1000 - 1025
|
ABC Transporters, Cholesterol Levels and Diabetes
Michael Hayden (Centre for Molecular Medicine & Therapeutics) |
1025 - 1050
|
HDL in the Intersection of Diabetes Mellitus and Atherosclerosis
Arnold von Eckardstein (Universitätsspital Zürich Institut) |
1050 - 1115
|
Greasing the Wheels for Abeta Clearance: New Roles for Brain HDL in
Alzheimer's Disease
Cheryl Wellington (University of British Columbia)
|
| 1115 - 1135 |
Break
|
| 1135 - 1225 |
The HDL Proteome
Discussion Leader: Ernst Schaefer (Tufts University) |
1135 - 1200
|
The Inextricable HDL Triad: Lipidome, Proteome and Functionality
John Chapman (Medical Faculty, University of Paris) |
1200 - 1225
|
Dynamic Remodeling of the HDL Proteome During Inflammation
Jay Heinecke (University of Washington)
|
| 1225 - 1315 |
HDL, Inflammation, and Autoimmunity
Discussion Leader: Christian Ehnholm (National Institute of Health and Welfare) |
1225 - 1250
|
Apolipoprotein A-I Attenuates Regulatory T Cells in Autoimmune LDLr-/-, ApoA-I-/- Mice
Mary Sorci-Thomas (Wake Forest University School of Medicine) |
1250 - 1315
|
Inflammatory Modulation of Reverse Cholesterol Transport
Muredach Reilly (University of Pennsylvania School of Medicine)
|
1315
1330 |
Group Photograph
Lunch |
| 1400 - 1600 |
Poster Viewing
|
| 1600 - 1900 |
Hosted Poster Session
|
1900
|
Dinner and Evening Debate: HDL is a Better Therapeutic Target than LDL for the Prevention of Vascular Disease
Moderator: Alan Chait (University of Washington)
Pro: Jacques Genest (McGill University)
Con: Jonathan Cohen (University of Texas Southwestern Medical Center at Dallas) |
| |
|
| Thursday, May 20 |
|
| 0730 - 0830 |
Breakfast
|
| 0830 - 0940 |
HDL Metabolism
Discussion Leader: Deneys van der Westhuyzen (University of Kentucky) |
0835 - 0900
|
Role of LCAT in HDL Metabolism and Atherosclerosis: Insight from LCAT Deficiency Syndromes
Laura Calabresi (University of Milano) |
0900 - 0925
|
Scavenger Receptor BI in Murine and Human Biology: State of the Art
Theo van Berkel (Universiteit Leiden) |
0925 - 0940
|
A Role for Scavenger Receptor BI in Human Cholesterol Homeostasis
Menno Vergeer (University of Amsterdam)
|
| 0940 - 1255 |
Established and Novel Therapeutics Related to HDL
Discussion Leaders: Philip Barter (The Heart Research Institute) and Andy Plump (Merck Research Laboratories) |
0940 - 1005
|
Structure and Function Studies of Anti-atherogenic ApoA-I Mimetic Peptides
Alan Remaley (NIH Clinical Center) |
1005 - 1030
|
Selective Functions of LXRalpha and LXRbeta in Lipid Metabolism and the Control of Atherosclerosis
Ira Schulman (University of Virginia)
|
| 1030 - 1050 |
Break
|
1050 - 1115
|
Proteolytic Degradation of ABCA1 as a Target for Anti-atherogenic Treatment
Shinji Yokoyama (Nagoya City University) |
1115 - 1140
|
Where Are We With CETP Inhibitors?
Ernst Schaefer (Tufts University) |
1140 - 1205
|
Niacin: New Understanding of an Old Lipid Drug
Andrew Taggart (Division of Cardiovascular Diseases, Merck Research Laboratories) |
1205 - 1230
|
Anti-inflammatory Properties of Niacin
Kerry-Anne Rye (The Heart Research Institute) |
1230 - 1255
|
Regulatory Hurdles in the Development of Drugs Affecting HDL
David Orloff (Clinical Research Organization, Medpace)
|
| 1300 |
Bagged lunch for take-away to enjoy the afternoon |
| 1400 - 1830 |
Afternoon on own
|
| 1830 - 2230 |
Conference Banquet |